样式: 排序: IF: - GO 导出 标记为已读
-
Current diagnosis and treatment of salivary gland-type tumors of the lung. Jpn. J. Clin. Oncol. (IF 2.4) Pub Date : 2023-11-28 Yoshitsugu Horio,Hiroaki Kuroda,Katsuhiro Masago,Hirokazu Matsushita,Eiichi Sasaki,Yutaka Fujiwara
Salivary gland-type tumors of the lung are thought to originate from the submucosal exocrine glands of the large airways. Due to their rare occurrence, reports of their study are limited to small-scale or case reports. Therefore, daily clinical practices often require a search for previous reports. In the last 20 years, several genetic rearrangements have been identified, such as MYB::NF1B rearrangements
-
A comparison of the incidence of ≥ grade 2 radiation pneumonitis between intensity-modulated radiotherapy and three-dimensional conformal radiotherapy in patients with unresectable non-small cell lung cancer treated with durvalumab after concurrent chemoradiotherapy. Jpn. J. Clin. Oncol. (IF 2.4) Pub Date : 2023-11-25 Masahiro Masuo,Eiko Shinohara,Masataka Kitano,Ryusuke Maruta,Satoshi Chonabayashi,Shun Endo,Suhei Matumoto,Naoki Nishiyama,Yumiko Machitori,Masayoshi Kobayashi
BACKGROUND Intensity-modulated radiation therapy (IMRT) has been increasingly used as a new radiation modality for unresectable non-small cell lung cancer (NSCLC). The risk factors for radiation pneumonitis (RP) during consolidation durvalumab following concurrent chemoradiotherapy (CCRT) using IMRT have not been thoroughly investigated. METHODS This retrospective study analyzed medical record data
-
Stepwise prolongation of overall survival from first to third generation EGFR-TKIs for EGFR mutation-positive non-small-cell lung cancer: the Tokushukai REAl-world Data project (TREAD 01). Jpn. J. Clin. Oncol. (IF 2.4) Pub Date : 2023-11-23 Kiyoaki Uryu,Yoshinori Imamura,Rai Shimoyama,Takahiro Mase,Yoshiaki Fujimura,Maki Hayashi,Megu Ohtaki,Keiko Otani,Makoto Hibino,Shigeto Horiuchi,Tomoya Fukui,Ryuta Fukai,Yusuke Chihara,Akihiko Iwase,Noriko Yamada,Yukihiro Tamura,Hiromasa Harada,Nobuaki Shinozaki,Asuka Tsuya,Masahiro Fukuoka,Hironobu Minami
OBJECTIVE The introduction of new-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) has afforded promising overall survival outcomes in clinical trials for non-small-cell lung cancer. We aim to investigate the current adoption rate of these agents and the real-world impact on overall survival among institutions. METHODS In a nationwide retrospective cohort study of
-
Projection of the number of new cases of breast cancer in the world. Jpn. J. Clin. Oncol. (IF 2.4) Pub Date : 2023-11-23 Sumiyo Okawa,Kumiko Saika
-
Not taking sick leave for gynecologic cancer treatment is negatively associated with returning to the same workplace. Jpn. J. Clin. Oncol. (IF 2.4) Pub Date : 2023-11-23 Keiichiro Nakamura,Hirofumi Matsuoka,Kotaro Kubo,Shinsuke Shirakawa,Naoyuki Ida,Junko Haraga,Chikako Ogawa,Kazuhiro Okamoto,Shoji Nagao,Hisashi Masuyama
BACKGROUND Gynecologic cancers are one of the most common types of malignancies in working-age women. We aimed to determine the factors that impede women from returning to the same workplace after treatment for such cancers. METHODS A questionnaire-based survey was conducted on 194 women who underwent treatment for gynecologic cancer at the Okayama University (≥1 year after cancer treatment and <65
-
Development and evaluation of a rapid one-step high sensitivity real-time quantitative PCR system for minor BCR-ABL (e1a2) test in Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Jpn. J. Clin. Oncol. (IF 2.4) Pub Date : 2023-11-20 Michihiro Hidaka,Koiti Inokuchi,Nobuhiko Uoshima,Naoto Takahashi,Nao Yoshida,Shuichi Ota,Hirohisa Nakamae,Hiromi Iwasaki,Kenichiro Watanabe,Yoshiyuki Kosaka,Norio Komatsu,Kuniaki Meguro,Yuho Najima,Tetsuya Eto,Takeshi Kondo,Shinya Kimura,Chikashi Yoshida,Yuichi Ishikawa,Masashi Sawa,Tomoko Hata,Keizo Horibe,Hiroatsu Iida,Takeshi Shimomura,Nobuaki Dobashi,Isamu Sugiura,Junya Makiyama,Naoyuki Miyagawa
OBJECTIVE Minimal residual disease assessment of BCR-ABL messenger ribonucleic acid levels is crucial in Philadelphia chromosome-positive acute lymphoblastic leukemia for prognosis and treatment planning. However, accurately quantifying minor BCR-ABL transcripts, which comprise 70% of Philadelphia chromosome-positive acute lymphoblastic leukemia cases, lacks a national-approved method. METHODS We developed
-
The impact of second transurethral resection on survival outcomes in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin therapy. Jpn. J. Clin. Oncol. (IF 2.4) Pub Date : 2023-11-16 Hiroshi Kikuchi,Takashige Abe,Makito Miyake,Haruka Miyata,Ryuji Matsumoto,Takahiro Osawa,Nobutaka Nishimura,Kiyohide Fujimoto,Junichi Inokuchi,Takahiro Yoneyama,Ryotaro Tomida,Kazuyuki Numakura,Yuto Matsushita,Kazumasa Matsumoto,Takuma Sato,Rikiya Taoka,Takashi Kobayashi,Takahiro Kojima,Yoshiyuki Matsui,Naotaka Nishiyama,Hiroshi Kitamura,Hiroyuki Nishiyama,Nobuo Shinohara
OBJECTIVE Several guidelines recommended that second transurethral resection should be performed in patients with diagnosis of high-risk non-muscle-invasive bladder cancer. However, therapeutic benefits of second transurethral resection before bacillus Calmette-Guérin intravesical instillation were conflicting amongst previous studies. We investigated the prognostic impact of second transurethral resection
-
Intraductal papillary growth of metastatic colorectal cancer. Jpn. J. Clin. Oncol. (IF 2.4) Pub Date : 2023-11-15 Shohei Kudo,Ryota Matsuki,Junji Shibahara,Yoshihiro Sakamoto
-
Investigation of eligibility for adjuvant therapy from real-world data of patients with urothelial carcinoma undergoing radical cystectomy and radical nephroureterectomy. Jpn. J. Clin. Oncol. (IF 2.4) Pub Date : 2023-11-15 Taisuke Matsue,Minoru Kato,Yuki Kosugi,Kota Ishizaki,Hiroo Masuda,Shoma Yamamoto,Yuji Takeyama,Nao Yukimatsu,Taiyo Otoshi,Takeshi Yamasaki,Katsuyuki Kuratsukuri,Junji Uchida
OBJECTIVE Adjuvant nivolumab prolonged disease-free survival compared with placebo in patients at high risk of recurrence following radical cystectomy or radical nephroureterectomy in the CheckMate 274 trial. However, the ideal eligibility criteria for adjuvant therapy in real-world clinical practice remain controversial. METHODS We retrospectively analyzed clinical data of 409 patients who underwent
-
Clinical response of pancreatic cancer bearing a germline BRCA2 p.I3169M fs*48 variant for platinum-based drug and PARP inhibitor. Jpn. J. Clin. Oncol. (IF 2.4) Pub Date : 2023-11-11 Risa Akahira,Koji Fukuda,Kazuhiro Shimazu,Taichi Yoshida,Daiki Taguchi,Hanae Shinozaki,Hiroshi Nanjyo,Hiroyuki Shibata
Pancreatic cancer is a malignancy with a high mortality rate, accounting for 37 000 people annually in Japan. It is rarely diagnosed in a resectable state, and effective medicines for its advanced stage are scarce. Some pancreatic cancer is hereditary, and ~10% have germline mutations of Breast cancer 1/2 (BRCA1/2). BRCA1/2 are key molecules involved in homologous recombination to repair DNA double-strand
-
Rare but clinically important salivary gland-type tumor of the lung: A review. Jpn. J. Clin. Oncol. (IF 2.4) Pub Date : 2023-11-10 Shinkichi Takamori,Yasushi Yatabe,Atsushi Osoegawa,Keiju Aokage,Hiroshige Yoshioka,Tomohiro Miyoshi,Takahiro Mimae,Makoto Endo,Aritoshi Hattori,Masaya Yotsukura,Tetsuya Isaka,Mitsuhiro Isaka,Tomohiro Maniwa,Ryu Nakajima,Shun-Ichi Watanabe
Salivary gland-type tumor (SGT) of the lung, which arises from the bronchial glands of the tracheobronchial tree, was first recognized in the 1950s. SGT represents less than 1% of all lung tumors and is generally reported to have a good prognosis. Mucoepidermoid carcinoma (MEC) and adenoid cystic carcinoma (ACC) are the two most common subtypes, comprising more than 90% of all SGTs. The reported 5-year
-
Protocol digest of a randomized controlled adaptive Phase II/III trial of neoadjuvant chemotherapy for Japanese patients with oesophagogastric junction adenocarcinoma: Japan Clinical Oncology Group Study JCOG2203 (NEO-JPEG). Jpn. J. Clin. Oncol. (IF 2.4) Pub Date : 2023-11-10 Ryosuke Kita,Yoshitomo Yanagimoto,Hiroshi Imazeki,Eisuke Booka,Takahiro Tsushima,Junki Mizusawa,Keita Sasaki,Haruhiko Fukuda,Yukinori Kurokawa,Hiroya Takeuchi,Ken Kato,Yuko Kitagawa,Narikazu Boku,Takaki Yoshikawa,Masanori Terashima,
Treatment strategies for oesophagogastric junction adenocarcinoma have not been standardized despite its poor prognosis due to differences in the incidence rates between Western countries and Asia. This randomized Phase II/III trial was initiated in June 2023 to determine which neoadjuvant chemotherapy regimen, docetaxel, oxaliplatin and S-1 or fluorouracil, oxaliplatin and docetaxel, is a more promising
-
Projection of the number of new cases of kidney and renal pelvis cancer in the world. Jpn. J. Clin. Oncol. (IF 2.4) Pub Date : 2023-11-05 Hadrien Charvat,Kayo Nakata
-
Survival analysis of high-grade salivary gland carcinoma adjusted for length bias due to delay in comprehensive genomic profiling. Jpn. J. Clin. Oncol. (IF 2.4) Pub Date : 2023-11-05 Kenya Kobayashi,Yuki Saito,Teru Kamogashira,Hidenori Kage,Osamu Fukuoka,Koji Yamamura,Toshiyuki Mukai,Katsutoshi Oda,Tatsuya Yamasoba
-
Letter to the editor: left-truncation bias should be considered in prognostic analysis using National Genomic Profiling Database. Jpn. J. Clin. Oncol. (IF 2.4) Pub Date : 2023-11-05 Masachika Ikegami
-
Advances in treatment of alveolar soft part sarcoma: an updated review. Jpn. J. Clin. Oncol. (IF 2.4) Pub Date : 2023-11-05 Tomohiro Fujiwara,Toshiyuki Kunisada,Eiji Nakata,Kenji Nishida,Hiroyuki Yanai,Tomoki Nakamura,Kazuhiro Tanaka,Toshifumi Ozaki
Alveolar soft part sarcoma is a rare neoplasm of uncertain histogenesis that belongs to a newly defined category of ultra-rare sarcomas. The neoplasm is characterized by a specific chromosomal translocation, der (17) t(X; 17)(p11.2;q25), that results in ASPSCR1-TFE3 gene fusion. The natural history of alveolar soft part sarcoma describes indolent behaviour with slow progression in deep soft tissues
-
Laparoscopic minor liver resection for hepatocellular carcinoma. Jpn. J. Clin. Oncol. (IF 2.4) Pub Date : 2023-11-05 Takashi Kokudo,Nobuyuki Takemura,Fuyuki Inagaki,Yuhi Yoshizaki,Fuminori Mihara,Yoshihiro Edamoto,Kazuhiko Yamada,Norihiro Kokudo
BACKGROUND Previous studies have suggested that laparoscopic liver resection for hepatocellular carcinoma is associated with lower postoperative complications compared with open liver resection. METHODS We conducted a retrospective analysis of 109 hepatocellular carcinoma patients who underwent minor liver resection at a Japanese tertiary care hospital from November 2010 to December 2022. RESULTS The
-
Adjuvant and neoadjuvant chemotherapy for biliary tract cancer: a review of randomized controlled trials. Jpn. J. Clin. Oncol. (IF 2.4) Pub Date : 2023-11-05 Kohei Nakachi,Naoto Gotohda,Etsuro Hatano,Satoshi Nara,Shinichiro Takahashi,Yasuyuki Kawamoto,Makoto Ueno
The first randomized controlled trial of adjuvant chemotherapy for biliary tract cancer was reported in 2002. Since then, studies have continued, with efficacy reported for capecitabine in 2018 and S-1 in 2023. Oral fluoropyrimidines have become established as the standard of care. This article reviews the evidence from the randomized controlled trials reported to date and those that are ongoing or
-
The first report of surgery for gynecological diseases using the hinotori™ surgical robot system. Jpn. J. Clin. Oncol. (IF 2.4) Pub Date : 2023-11-05 Shinichi Togami,Takuro Higashi,Akio Tokudome,Mika Fukuda,Mika Mizuno,Shintaro Yanazume,Hiroaki Kobayashi
OBJECTIVE This study aimed to report the first surgery for gynecological diseases using a new robotic platform, the hinotori™, and validate its feasibility in clinical settings. METHODS The world's first robot-assisted total hysterectomy for a gynecological ailment was carried out at Kagoshima University Hospital in December 2022 utilizing the hinotori™ surgical robot system. Eleven other patients
-
Effectiveness of online mindfulness-based interventions for cancer patients: a systematic review and meta-analysis. Jpn. J. Clin. Oncol. (IF 2.4) Pub Date : 2023-11-05 Meiling Fan,Yang Wang,Lufang Zheng,Miao Cui,Xiuling Zhou,Zengxia Liu
PURPOSE Cancer is the second leading cause of mortality worldwide. Cancer negatively affects individuals' quality of life and overall health. Mindfulness-based interventions appear to be promising in the reduction of cancer- and treatment-related symptoms. This review aimed to determine the effectiveness of online mindfulness-based interventions on distress, anxiety, depression, stress, mindfulness
-
The impact of osteosarcopenia in patients with unresectable or recurrent biliary tract cancer receiving palliative chemotherapy. Jpn. J. Clin. Oncol. (IF 2.4) Pub Date : 2023-11-05 Tsuyoshi Takeda,Takeshi Okamoto,Takashi Sasaki,Tatsuki Hirai,Takahiro Ishitsuka,Manabu Yamada,Hiroki Nakagawa,Takafumi Mie,Takaaki Furukawa,Akiyoshi Kasuga,Masato Ozaka,Naoki Sasahira
BACKGROUND Osteosarcopenia is a newly described syndrome that has been reported to be associated with worse outcomes in various types of cancer. However, its impact on survival in biliary tract cancer remains unclear. This study evaluated the impact of osteosarcopenia on survival in patients with unresectable or recurrent biliary tract cancer. METHODS A total of 306 patients with unresectable or recurrent
-
Non-operative management involving chemoradiation therapy combined with high-dose-rate brachytherapy for T3 rectal cancer using a vaginal shielded cylindrical applicator: a technical report. Jpn. J. Clin. Oncol. (IF 2.4) Pub Date : 2023-11-05 Naoya Murakami,Kanako Kojima,Kae Okuma,Tairo Kashihara,Satoshi Nakamura,Wakako Shimizu,Ryuichiro Suda,Hiroshi Igaki,Naoto Shikama
It has been shown that a group of rectal cancer patients will achieve a pathological complete response following preoperative chemoradiotherapy, and non-operative management has recently gained attention. To escalate the tumour dose and increase the likelihood of pathological complete response, brachytherapy can play an important role in safely increasing the total dose. However, at the time this report
-
Clinical outcomes of head and neck mucosal melanoma treated with surgery: a single-center study in Japan. Jpn. J. Clin. Oncol. (IF 2.4) Pub Date : 2023-11-05 Go Omura,Kenjiro Namikawa,Toshihiko Sakai,Kohtaro Eguchi,Yoshifumi Matsumoto,Azusa Sakai,Kenya Kobayashi,Eiji Nakano,Dai Ogata,Fumihiko Matsumoto,Taisuke Mori,Naoya Yamazaki,Seiichi Yoshimoto
BACKGROUND Head and neck mucosal melanomas are rare malignancies. Although the prognosis is poor owing to the high incidence of distant metastases, locoregional control remains important. It is difficult to obtain results in a large cohort because of its rarity. This study aimed to elucidate the survival outcomes of patients with head and neck mucosal melanoma treated with surgery in Japan. METHODS
-
Current status of vulvar cancer in Japan: analysis of the Japanese Gynecologic Oncology Group nationwide survey study. Jpn. J. Clin. Oncol. (IF 2.4) Pub Date : 2023-11-05 Shin Nishio
This review provides an overview of the current status of vulvar cancer in Japan, focusing specifically on the findings from the Japanese Gynecologic Oncology Group nationwide survey study. The author offers a comprehensive summary of the current status of vulvar cancer in Japan, along with an exploration of the molecular mechanisms underlying the disease. Notably, the review highlights the concerning
-
Elevated preoperative plasma D-dimer level was an independent prognostic factor for patients with PDAC after curative resection: a retrospective analysis. Jpn. J. Clin. Oncol. (IF 2.4) Pub Date : 2023-11-05 Li Zhifei,Liang Yuexiang,Chang Shaofei,Li Shuo,Wang Hongwei,Gao Chuntao
OBJECTIVE In this study, the relationship between preoperative plasma D-dimer level and overall survival and recurrence free survival were evaluated in patients with curative resection of pancreatic ductal adenocarcinoma. METHODS Preoperative plasma D-dimer level of 573 patients with pancreatic ductal adenocarcinoma were collected. The univariate and multivariate Cox hazard models were used to identify
-
Efficacy of an enhanced recovery after surgery pathway to manage pain, nausea and vomiting after head and neck surgeries with free tissue transfer reconstruction. Jpn. J. Clin. Oncol. (IF 2.4) Pub Date : 2023-11-05 Takayuki Imai,Teiko Takasago,Yumiko Momma,Tomoyo Chiba,Ayako Nakanome,Sinkichi Morita,Kohsei Hasegawa,Kazue Ito,Takahiro Goto,Yukinori Asada
BACKGROUND Pain and post-operative nausea and vomiting are the main factors that impair the quality of recovery after surgery. Very few reports have analyzed patient-reported outcomes to investigate the efficacy of an enhanced recovery after surgery protocol to alleviate these symptoms after head and neck surgeries with free tissue transfer reconstruction. METHODS We investigated post-operative pain
-
Consulting a neurosurgeon upon initial medical assessment reduces the time to the first surgery and potentially contributes to improved prognosis for glioblastoma patients. Jpn. J. Clin. Oncol. (IF 2.4) Pub Date : 2023-11-05 Daisuke Kawauchi,Makoto Ohno,Yasuji Miyakita,Masamichi Takahashi,Shunsuke Yanagisawa,Takaki Omura,Akihiko Yoshida,Yuko Kubo,Hiroshi Igaki,Koichi Ichimura,Yoshitaka Narita
BACKGROUND The neurological status of glioblastoma patients rapidly deteriorates. We recently demonstrated that early diagnosis and surgery within 3 weeks from the initial symptoms are associated with improved survival. While glioblastoma is a semi-urgent disease, the prehospital behaviors and clinical outcomes of glioblastoma patients are poorly understood. We aimed to disclose how prehospital patient
-
Spontaneously expectorated EGFR-mutant non-small-cell lung cancer. Jpn. J. Clin. Oncol. (IF 2.4) Pub Date : 2023-11-05 Toshiyuki Sumi,Kotomi Terai,Hirofumi Chiba
-
Significance of tumor size and number of positive nodes in patients with FIGO 2018 stage IIIC1 cervical cancer. Jpn. J. Clin. Oncol. (IF 2.4) Pub Date : 2023-11-01 Michihide Maeda,Seiji Mabuchi,Mina Sakata,Satoki Deguchi,Reisa Kakubari,Shinya Matsuzaki,Tsuyoshi Hisa,Shoji Kamiura
OBJECTIVE This study aimed to investigate the prognostic significance of tumor size and number of positive pelvic lymph nodes (PLN) in International Federation of Gynecology and Obstetrics (FIGO) 2018 stage IIIC1 cervical cancer patients. METHODS Clinical data from 626 women with cervical cancer treated at Osaka International Cancer Center in 2010-2020 were retrospectively reviewed. Using the cutoff
-
Comprehensive genomic profiling testing in Japanese castration-resistant prostate cancer patients: results of a single-center retrospective cohort study. Jpn. J. Clin. Oncol. (IF 2.4) Pub Date : 2023-10-28 Takafumi Fukushima,Keisuke Goto,Tetsutaro Hayashi,Kenichiro Ikeda,Tomoya Hatayama,Ryoken Yamanaka,Kyosuke Iwane,Ryo Tasaka,Yuki Kohada,Kenshiro Takemoto,Kohei Kobatake,Akihiro Goriki,Asuka Toshida,Hikaru Nakahara,Masanori Motonaga,Kentaro Tokumo,Yasutoshi Fujii,C Nelson Hayes,Wataru Okamoto,Toshio Kubo,Takashi Matsumoto,Masaki Shiota,Noboru Yamamoto,Yuji Urabe,Eiso Hiyama,Koji Arihiro,Takao Hinoi,Nobuyuki
OBJECTIVE Comprehensive genomic profiling testing using a hybrid-capture next-generation sequencing is commonly used in clinical practice to employ precision medicine in cancer treatment worldwide. In this study, we aimed to analyze the profiles obtained using comprehensive genomic profiling testing that was performed in Japanese castration-resistant prostate cancer patients and to discuss the genetic
-
Trend in overall survival from the start of first-line chemotherapy in patients with metastatic urothelial carcinoma. Jpn. J. Clin. Oncol. (IF 2.4) Pub Date : 2023-10-26 Shoma Yamamoto,Minoru Kato,Taisuke Matsue,Nao Yukimatsu,Yuji Takeyama,Taiyo Otoshi,Takeshi Yamasaki,Katsuyuki Kuratsukuri,Junji Uchida
New approaches involving immune checkpoint inhibitors and antibody-drug conjugates prolong overall survival in patients with metastatic urothelial carcinoma. However, the access to such systemic therapy in clinical practice is suboptimal, and whether these agents improve overall survival in patients with metastatic urothelial carcinoma over time remains unclear. Hence, we investigated the overall survival
-
Value of GPR, APPRI and FIB-4 in the early diagnosis of hepatocellular carcinoma: a prospective cohort study. Jpn. J. Clin. Oncol. (IF 2.4) Pub Date : 2023-10-21 Lizhen Zhang,Siyu Li,Desheng Zhang,Chun Yin,Zhongge Wang,Ruirui Chen,Ning Cheng,Yana Bai
OBJECTIVE There is an urgent need for novel biomarkers that are inexpensive, effective and easily accessible to complement the early diagnosis of hepatocellular carcinoma. This study aimed to analyze the relationship between serum gamma-glutamate-transpeptidase to platelet ratio, alkaline phosphatase-to-platelet ratio index, fibrosis index based on four factors and the risk of hepatocellular carcinoma
-
Conventional versus underwater endoscopic resection for superficial non-ampullary duodenal epithelial tumours. Jpn. J. Clin. Oncol. (IF 2.4) Pub Date : 2023-10-21 Hajime Miyazaki,Osamu Dohi,Tsugitaka Ishida,Mayuko Seya,Katsuma Yamauchi,Hayato Fukui,Takeshi Yasuda,Takuma Yoshida,Naoto Iwai,Toshifumi Doi,Ryohei Hirose,Ken Inoue,Akihito Harusato,Naohisa Yoshida,Kazuhiko Uchiyama,Tomohisa Takagi,Takeshi Ishikawa,Hideyuki Konishi,Yukiko Morinaga,Mitsuo Kishimoto,Yuji Naito,Yoshito Itoh
BACKGROUND AND OBJECTIVE Several endoscopic resection methods have been developed as less invasive treatments for superficial non-ampullary duodenal epithelial tumours. This study aimed to compare outcomes of conventional endoscopic mucosal resection and underwater endoscopic mucosal resection for superficial non-ampullary duodenal epithelial tumours, including resection depth and rate of the muscularis
-
Clinical impact of sarcopenia for overweight or obese patients with colorectal cancer. Jpn. J. Clin. Oncol. (IF 2.4) Pub Date : 2023-10-17 Wei-Zhe Chen,Feng Lin,Ding-Ye Yu,Qi Ren,Feng-Min Zhang,Zi-Le Shen,Wen-Hao Chen,Qian-Tong Dong,Zhen Yu
BACKGROUND Sarcopenia, overweight and obesity are all dynamic changes in body composition, which may have a negative effect on the prognosis for patients with colorectal cancer. The aim of this study was to investigate the predictive role of sarcopenia on overweight or obese patients with colorectal cancer. METHODS We conducted an observative study on the population of overweight or obese patients
-
Real-world prostate-specific antigen response and progression to castration-resistant prostate cancer among men with metastatic castration-sensitive prostate cancer treated with apalutamide: a multi-institutional study in the Chu-shikoku Japan Urological Consortium. Jpn. J. Clin. Oncol. (IF 2.4) Pub Date : 2023-10-14 Yoichiro Tohi,Takuma Kato,Keita Kobayashi,Kei Daizumoto,Hideo Fukuhara,Shin Ohira,Satoshi Katayama,Ryutaro Shimizu,Atsushi Takamoto,Kenichi Nishimura,Kenichiro Ikeda,Taichi Nagami,Yushi Hayashida,Hiromi Hirama,Hirohito Naito,Ryotaro Tomida,Yutaro Sasaki,Shinkuro Yamamoto,Shinjiro Shimizu,Mikio Sugimoto,
BACKGROUND Japanese men receiving apalutamide often experience skin-adverse events (AEs), possibly requiring treatment interruption or dose reduction. However, concerns have arisen regarding the impact of these adjustments on the efficacy of apalutamide. Our study evaluated the efficacy, safety, and persistence of apalutamide in men with metastatic castration-sensitive prostate cancer (mCSPC). METHODS
-
Predictive factors and oncological outcomes of pathological T3a upstaging in patients with clinical T1 renal cell carcinoma undergoing partial nephrectomy. Jpn. J. Clin. Oncol. (IF 2.4) Pub Date : 2023-10-14 Ryo Ishiyama,Kenji Omae,Tsunenori Kondo,Junpei Iizuka,Kazuhiko Yoshida,Hironori Fukuda,Hidekazu Tachibana,Hiroki Ishihara,Hirohito Kobayashi,Toshio Takagi
OBJECTIVES To investigate predictive factors and oncological outcomes of pathological T3a upstaging in renal cell carcinoma patients who were initially diagnosed as clinical T1 and treated with partial nephrectomy. METHODS AND MATERIALS The clinical records and survival data of 1617 patients, who had undergone partial nephrectomy for clinical T1 renal cell carcinoma at Tokyo Women's Medical University
-
Use of clinical variables for preoperative prediction of lymph node metastasis in endometrial cancer. Jpn. J. Clin. Oncol. (IF 2.4) Pub Date : 2023-10-09 Yuta Ueno,Emiko Yoshida,Shuko Nojiri,Tomoyasu Kato,Takashi Ohtsu,Toshiyuki Takeshita,Shunji Suzuki,Hiroshi Yoshida,Ken Kato,Masayoshi Itoh,Tsuguto Notomi,Kengo Usui,Takashi Sozu,Yasuhisa Terao,Hideya Kawaji,Hisamori Kato
OBJECTIVE Endometrial cancer is the most common gynaecological cancer, and most patients are identified during early disease stages. Noninvasive evaluation of lymph node metastasis likely will improve the quality of clinical treatment, for example, by omitting unnecessary lymphadenectomy. METHODS The study population comprised 611 patients with endometrial cancer who underwent lymphadenectomy at four
-
End-of-life walking ability in cancer patients with spinal metastases. Jpn. J. Clin. Oncol. (IF 2.4) Pub Date : 2023-10-09 Ryoko Sawada,Yusuke Shinoda,Takahiro Ohki,Yuki Ishibashi,Hiroshi Kobayashi,Yoshitaka Matsubayashi,Sakae Tanaka,Nobuhiko Haga
BACKGROUND Even terminal cancer patients desire to walk to the toilet by themselves until the very last day. This study aimed to describe the walking ability of patients with spinal metastases at the end-of-life stage and identify the factors affecting this ability. METHODS Among 527 patients who first visited our multidisciplinary team for bone metastasis between 2013 and 2016, 56 patients who had
-
Baseline characteristics may impact treatment duration of cabazitaxel in patients with mCRPC: a subanalysis of data from a post-marketing surveillance. Jpn. J. Clin. Oncol. (IF 2.4) Pub Date : 2023-10-06 Nobuaki Matsubara,Hideyasu Matsuyama,Hirotaka Kazama,Takeshi Seto,Yoshinori Sunaga,Kazuhiro Suzuki
OBJECTIVE Cabazitaxel has demonstrated improvements in overall survival among patients with metastatic castration-resistant prostate cancer (mCRPC) in the pivotal comparison clinical trials TROPIC, PROSELICA and CARD. However, these trials include mCRPC patients with similar characteristics, and there are limited data on how baseline characteristics affect treatment discontinuation in the patient population
-
Influence of serum Gas6 levels on prognosis in patients with hepatocellular carcinoma. Jpn. J. Clin. Oncol. (IF 2.4) Pub Date : 2023-10-05 Manabu Hayashi,Kazumichi Abe,Tatsuro Sugaya,Yosuke Takahata,Masashi Fujita,Atsushi Takahashi,Hiromasa Ohira
OBJECTIVE The prediction of prognosis in hepatocellular carcinoma patients is important for switching treatment. The association between circulating growth arrest-specific 6 levels and prognosis in hepatocellular carcinoma patients is unknown. METHODS We retrospectively analysed the association between serum growth arrest-specific 6 levels and clinical findings in 132 patients with hepatocellular carcinoma
-
A phase III randomized controlled trial comparing local field with additional prophylactic irradiation in chemoradiotherapy for clinical-T1bN0M0 esophageal cancer: ARMADILLO trial (JCOG1904). Jpn. J. Clin. Oncol. (IF 2.4) Pub Date : 2023-10-05 Keita Sasaki,Motoo Nomura,Ken Kato,Katsuyuki Sakanaka,Yoshinori Ito,Tomohiro Kadota,Ryunosuke Machida,Tomoko Kataoka,Keiko Minashi,Yasuhiro Tsubosa,Takeshi Kajiwara,Haruhiko Fukuda,Hiroya Takeuchi,Takashi Mizowaki,Yasumasa Nishimura,Yuko Kitagawa
Chemoradiotherapy has been considered as one of the standard treatment options for clinical T1bN0M0 esophageal squamous cell carcinoma with organ preservation. However, 20% of patients develop locoregional recurrence after chemoradiotherapy, which requires salvage treatment including salvage surgery and endoscopic resection. Salvage surgery can cause complications and treatment-related death. Interestingly
-
Real-world treatment outcomes of metastatic biliary tract cancer patients in Japan: the Tokushukai REAl-world data project 04 (TREAD 04). Jpn. J. Clin. Oncol. (IF 2.4) Pub Date : 2023-10-05 Rai Shimoyama,Yoshinori Imamura,Kiyoaki Uryu,Takahiro Mase,Masataka Taguri,Tadahisa Okuda,Yoshiaki Fujimura,Maki Hayashi,Satomi Tanaka,Keiji Sawamukai,Hironobu Minami
OBJECTIVES To investigate temporal trends in treatment patterns and prognostic factors for overall survival in patients with metastatic biliary tract cancer. METHODS From the Tokushukai REAl-world Data project, we identified 945 patients with metastatic biliary tract cancer treated with gemcitabine, tegafur/gimeracil/oteracil, gemcitabine plus cisplatin, gemcitabine plus tegafur/gimeracil/oteracil
-
-
-
Editorial for review series of adjuvant and neoadjuvant. Jpn. J. Clin. Oncol. (IF 2.4) Pub Date : 2023-10-04 Yoshihiro Sakamoto
-
Clinical development of immune checkpoint inhibitors in Japan-the same goal, different paths. Jpn. J. Clin. Oncol. (IF 2.4) Pub Date : 2023-10-04 Ikuo Sekine
-
The sarcopenia index measured using the lumbar paraspinal muscle is associated with prognosis in endometrial cancer. Jpn. J. Clin. Oncol. (IF 2.4) Pub Date : 2023-10-04 Kaname Uno,Nobuhisa Yoshikawa,Kazuhisa Kitami,Sho Mori,Takahiro Shibata,Shohei Iyoshi,Hiroki Fujimoto,Kazumasa Mogi,Masato Yoshihara,Satoshi Tamauchi,Yoshiki Ikeda,Akira Yokoi,Kazuyoshi Kato,Tsutomu Hoshiba,Hidenori Oguchi,Hiroaki Kajiyama
OBJECTIVE The number of type-II endometrial cancer patients has been increasing and the prognosis is not favorable. We aim to investigate whether sarcopenia index in any of several different muscles could serve as a novel biomarker of prognosis in patients with type-II endometrial cancer. METHODS We retrospectively investigated a total of 194 patients at four hospitals. Ninety patients were treated
-
Real-world efficacy and safety of cabozantinib following immune checkpoint inhibitor failure in Japanese patients with advanced renal cell carcinoma. Jpn. J. Clin. Oncol. (IF 2.4) Pub Date : 2023-10-04 Hiroki Ishihara,Yuki Nemoto,Hidekazu Tachibana,Hironori Fukuda,Kazuhiko Yoshida,Hirohito Kobayashi,Junpei Iizuka,Yasunobu Hashimoto,Tsunenori Kondo,Toshio Takagi
BACKGROUND Real-world data of cabozantinib after failure of immune checkpoint inhibitors for advanced renal cell carcinoma in Japanese population are limited. Additionally, prognostic factors of cabozantinib in this setting are still unknown. METHODS We retrospectively evaluated data of 56 patients treated with cabozantinib subsequent to failed immune checkpoint inhibitors at four institutions. Regarding
-
Current prognostic factors of advanced gastric cancer patients treated with chemotherapy: real world data from a Japanese 12 institutions. Jpn. J. Clin. Oncol. (IF 2.4) Pub Date : 2023-10-04 Shumpei Yamamoto,Hiromitsu Kanzaki,Chihiro Sakaguchi,Hirokazu Mouri,Takao Tsuzuki,Junichiro Nasu,Sayo Kobayashi,Tatsuya Toyokawa,Yuka Obayashi,Masafumi Inoue,Ryo Kato,Minoru Matsubara,Masahide Kita,Hiroyuki Okada
BACKGROUND Understanding the prognostic factors of advanced gastric cancer before starting chemotherapy is important to determine personalized treatment strategies. However, the details of chemotherapy and the prognosis of advanced gastric cancer patients have changed with the time and environment. The aim of this study was to understand the current reality of chemotherapy and to estimate the prognostic
-
Increasing age predicts adverse pathology including intraductal carcinoma of the prostate and cribriform patterns in deferred radical prostatectomy after upfront active surveillance for Gleason grade group 1 prostate cancer: analysis of prospective observational study cohort. Jpn. J. Clin. Oncol. (IF 2.4) Pub Date : 2023-10-04 Yoichiro Tohi,Ryou Ishikawa,Takuma Kato,Jimpei Miyakawa,Ryuji Matsumoto,Keiichiro Mori,Koji Mitsuzuka,Junichi Inokuchi,Masafumi Matsumura,Kenichiro Shiga,Hirohito Naito,Yasuo Kohjimoto,Norihiko Kawamura,Masaharu Inoue,Shusuke Akamatsu,Naoki Terada,Yoshiyuki Miyazawa,Shintaro Narita,Reiji Haba,Mikio Sugimoto
BACKGROUND In men undergoing upfront active surveillance, predictors of adverse pathology in radical prostatectomy specimens, including intraductal carcinoma of the prostate and cribriform patterns, remain unknown. Therefore, we aimed to examine whether adverse pathology in radical prostatectomy specimens could be predicted using preoperative patient characteristics. METHODS We re-reviewed available
-
Dose-escalation part of Phase I study of single-agent mosunetuzumab in Japanese patients with relapsed/refractory B-cell non-Hodgkin lymphoma. Jpn. J. Clin. Oncol. (IF 2.4) Pub Date : 2023-10-04 Wataru Munakata,Koji Izutsu,Yuko Mishima,Hirokazu Nagai,Yuko Ishihara,Junji Suzumiya,Yuzuru Kanakura,Toshihiro Nanki,Takeshi Miyake,Atsuko Kawasaki,Tatsuya Yoshinaga,Kenichi Ishizawa
OBJECTIVE This dose-escalation part of an ongoing Phase I study assessed the tolerability, safety and pharmacokinetics of mosunetuzumab in Japanese patients with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL). METHODS Mosunetuzumab was administered intravenously, with step-up dosing in a 3 + 3 design, on Days 1, 8 and 15 of Cycle 1, and Day 1 of each subsequent 21-day cycle for up to 17 cycles
-
A multicentre retrospective study on extra-thoracic solitary fibrous tumour: preoperative MRI findings predict intraoperative findings and postoperative prognosis. Jpn. J. Clin. Oncol. (IF 2.4) Pub Date : 2023-10-04 Hiroto Kamoda,Tsukasa Yonemoto,Akira Kawai,Toru Hiruma,Shintaro Iwata,Robert Nakayama,Hiroshi Kobayashi,Toshihide Hirai,Masato Saito,Takeshi Ishii
OBJECTIVE The present study investigated the relationships between the preoperative and operative findings of solitary fibrous tumour (SFT) and between preoperative findings and prognosis. METHODS We reviewed 50 SFT patients treated at our musculoskeletal oncology hospital group. We analyzed preoperative clinical findings, particularly MRI imaging findings, and intraoperative information as well as
-
Impact of postoperative complications on long-term survival in bladder cancer patients. Jpn. J. Clin. Oncol. (IF 2.4) Pub Date : 2023-10-04 Takashige Abe,Shuhei Yamada,Hiroshi Kikuchi,Ataru Sazawa,Hidenori Katano,Hidetaka Suzuki,Ichiro Takeuchi,Keita Minami,Ken Morita,Kunihiko Tsuchiya,Norikata Takada,Shintaro Maru,Soshu Sato,Takanori Yamashita,Tango Mochizuki,Tomoshige Akino,Yoshihiro Sasaki,Yuichiro Shinno,Norihiro Murahashi,Takafumi Kawazu,Jun Furumido,Haruka Miyata,Ryuji Matsumoto,Takahiro Osawa,Sachiyo Murai,Nobuo Shinohara
OBJECTIVE To determine the impact of postoperative complications on long-term survival outcomes in patients with bladder cancer undergoing radical cystectomy. METHODS This retrospective multi-institutional study included 766 bladder cancer patients who underwent radical cystectomy between 2011 and 2017. Patient characteristics, perioperative outcomes, all complications within 90 days after surgery
-
Characteristics and therapeutic strategies of brain and cranial radiation-induced sarcoma: analysis of 165 cases from our case experience and comprehensive review. Jpn. J. Clin. Oncol. (IF 2.4) Pub Date : 2023-10-04 Shumpei Onishi,Fumiyuki Yamasaki,Yasuyuki Kinoshita,Vishwa J Amatya,Takeshi Takayasu,Ushio Yonezawa,Akira Taguchi,Yukari Go,Yukio Takeshima,Nobutaka Horie
BACKGROUND Radiation-induced sarcoma (RIS) is among the neoplasms potentially caused by radiation therapy (RT) for brain tumors. However, the clinical characteristics of and ideal treatment for RIS are unclear. We analysed our case experience and conducted a comprehensive literature review to reveal the characteristics of brain and cranial RIS. METHODS We analysed 165 cases of RIS from the literature
-
Clinical characterization of patients with gBRCA1/2 mutation-positive unresectable pancreatic cancer: a multicenter prospective study. Jpn. J. Clin. Oncol. (IF 2.4) Pub Date : 2023-10-03 Tomohiro Kubo,Joji Muramatsu,Yohei Arihara,Ayako Murota,Kazuma Ishikawa,Makoto Yoshida,Hiroyuki Nagashima,Fumito Tamura,Yuki Ikeda,Makoto Usami,Michihiro Ono,Hajime Nakamura,Daichi Watanabe,Takanori Shibata,Kaoru Kasahara,Akihiro Sakurai,Kohichi Takada
BACKGROUND Accumulating evidence has demonstrated platinum-based chemotherapy followed by maintenance therapy with a poly Adenosine diphosphate (ADP)-ribose polymerase inhibitor (olaparib) show benefits in unresectable pancreatic cancer with a germline (g)BRCA1/2 mutation. Evaluation of the germline BRCA1 and BRCA2 mutation is essential for making decisions on a treatment strategy for patients with
-
Definitive radiotherapy for nasopharyngeal carcinoma in Japan: analysis of cases in the National Head and Neck Cancer Registry from 2011 to 2014. Jpn. J. Clin. Oncol. (IF 2.4) Pub Date : 2023-10-01 Yutaro Koide,Takeshi Kodaira,Megumi Kitayama,Daisuke Kawakita,Tadaaki Kirita,Seiichi Yoshimoto,Munenaga Nakamizo,Ken-Ichi Nibu
OBJECTIVE This study aimed to analyze the nationwide prognosis of patients with nasopharyngeal carcinoma who underwent definitive radiotherapy in Japan, utilizing the National Head and Neck Cancer Registry data. METHODS A total of 741 patients diagnosed with primary nasopharyngeal carcinoma were screened from 2011 to 2014. The inclusion criteria were histologically proven nasopharyngeal squamous cell
-
Squamous cell carcinoma of the eyelid. Jpn. J. Clin. Oncol. (IF 2.4) Pub Date : 2023-09-23 Yasuyoshi Sato,Shunji Takahashi,Takashi Toshiyasu,Hideki Tsuji,Nobuhiro Hanai,Akihiro Homma
Eyelid squamous cell carcinoma is a major type of rare eyelid cancer, together with basal cell carcinoma and sebaceous gland carcinoma. It is a painless disease that progresses slowly and is often detected by the appearance of nodules or plaques. Risk factors include exposure to ultraviolet light, fair skin, radiation and human papillomavirus infection. The standard treatment is surgical removal, and
-
Efficacy and safety of olaparib, olaparib plus bevacizumab and niraparib maintenance treatment in Japanese patients with platinum-sensitive advanced ovarian cancer. Jpn. J. Clin. Oncol. (IF 2.4) Pub Date : 2023-09-14 Keiichiro Nakamura,Hirofumi Matsuoka,Masae Yorimitsu,Mariko Ogawa,Miho Kanemori,Kotaro Sueoka,Ayumi Kozai,Hiroko Nakamura,Tomoko Haruma,Yuko Shiroyama,Yuu Hayata,Hirokazu Sugii,Akiko Ueda,Shuichi Kurihara,Saiko Urayama,Miyuki Shimizu,Hisashi Masuyama
OBJECTIVE To investigate whether maintenance treatment could be safely and effectively performed with olaparib, olaparib plus bevacizumab and niraparib in platinum-sensitive advanced ovarian cancer at multiple institutions in Japan. METHODS We investigated progression-free survival and adverse events in 117 patients with platinum-sensitive advanced ovarian cancer treated with maintenance therapy. RESULTS
-
Overall signature of acquired KRAS gene changes in advanced non-small cell lung cancer patient with EGFR-TKI resistance. Jpn. J. Clin. Oncol. (IF 2.4) Pub Date : 2023-09-14 Jie Zheng,Yuanyao Dou,Daijuan Huang,Yubo Wang,Rui Han,Chen Hu,Mengxiao Zhu,Conghua Lu,Caiyu Lin,Di Wu,Yihui Liu,Huan Tang,Tingting He,Weilin Jiang,Yong He
OBJECTIVE Numerous scattered case studies continue to demonstrate a strong correlation between acquired KRAS mutations and epidermal growth factor receptor-tyrosine kinase inhibitor resistance in non-small cell lung cancer. However, the comprehensive understanding of the KRAS pathway following the failure of epidermal growth factor receptor-tyrosine kinase inhibitor therapy remains limited. METHODS
-
Comparison of pre-operative and post-operative radiotherapy in patients with localized myxoid liposarcoma. Jpn. J. Clin. Oncol. (IF 2.4) Pub Date : 2023-09-07 Tomoya Masunaga,Shinji Tsukamoto,Kanya Honoki,Hiromasa Fujii,Akira Kido,Manabu Akahane,Yasuhito Tanaka,Andreas F Mavrogenis,Costantino Errani,Akira Kawai
BACKGROUND Myxoid liposarcoma is more radiosensitive than other soft tissue sarcomas, and radiotherapy has been reported to reduce tumour size. This study was performed to compare the rates of local recurrence, survival and wound complications between pre- and post-operative radiotherapy for localized myxoid liposarcoma. METHODS From the Japanese Nationwide Bone and Soft Tissue Tumor Registry database